HIV-Exposed Neonates Could Be Studied In Single-Dose P/K Trials – FDA Cmte.
Executive Summary
HIV-exposed neonates could be enrolled in single-dose pharmacokinetic trials for new antiretroviral drugs when the drugs' safety and efficacy are first established in older children, FDA's Anti-Infective Drugs Pediatric Advisory Subcommittee said March 3